Management of Toxicities with Targeted Therapies for Breast Cancer
Staying up-to-date with the available treatment options is important to clinicians integrating new evidence-based data into their clinical practice, and being familiar with their toxicity profiles is important to optimize patient outcomes.
Category
  • Breast Cancer
Format
  • Recorded Webcast
Credits
  • AAPA Category 1 CME credit
  • ACPE contact hours
  • AMA PRA Category 1 Credit™
  • ANCC contact hours
  • Participation
Practical Application of Immuno-Oncology in Renal Cell Carcinoma
The goal of this activity is to improve participants’ competence in and performance at applying practice-changing clinical data, expert recommendations, and guidelines to optimize the use of immuno-oncology–based combinations in the care of their patients with RCC.
Category
  • Kidney Cancer
Format
  • Recorded Webcast
Credits
  • AAPA Category 1 CME credit
  • ACPE contact hours
  • AMA PRA Category 1 Credit™
  • ANCC contact hours
  • Participation
Archived Monthly Oncology Tumor Boards: A Multidisciplinary Approach to Individualized Patient Care - Multiple Myeloma
Discussing specific patient cases, providing the rationale for the treatment choices based on expert experience and recent data from trials, and outlining strategies to provide adequate supportive care will assist clinicians treating transplant ineligible and elderly patients with multiple myeloma in making optimal treatment decisions and improving patient outcomes.
Category
  • Multiple Myeloma
Format
  • Recorded Webcast
Credits
  • AAPA Category 1 CME credit
  • ACPE contact hours
  • AMA PRA Category 1 Credit™
  • ANCC contact hours
  • CCM clock hours
  • Participation
Archived Monthly Oncology Tumor Boards: A Multidisciplinary Approach to Individualized Patient Care - Lung Cancer
For each of the emerging therapies described (bevacizumab, PARP inhibitors, and HIPEC), the treatment settings, patient selection criteria, and other therapies used in conjunction have varied widely across clinical trials. This has led to much discussion and likely confusion regarding the exact clinical contexts in which these new options should be considered.
Category
  • Lung Cancers
Format
  • Recorded Webcast
Credits
  • AAPA Category 1 CME credit
  • ACPE contact hours
  • AMA PRA Category 1 Credit™
  • ANCC contact hours
  • CCM clock hours
  • Participation
NCCN Guidelines® Insights - Primary Cutaneous Lymphomas, Version 2.2020
Mycosis fungoides (MF) is the most common subtype of cutaneous T-cell lymphoma (CTCL), and Sézary syndrome (SS) is a rare erythrodermic and leukemic subtype of CTCL characterized by significant blood involvement.
Category
  • Lymphoma
Format
  • Monograph/Journal Supplement
Credits
  • AAPA Category 1 CME credit
  • ACPE contact hours
  • AMA PRA Category 1 Credit™
  • ANCC contact hours
  • Participation
Practical Use of Next Generation Sequencing in Metastatic Disease
Next generation sequencing methods are increasingly being utilized to match patients with targeted therapies.
Category
  • Diagnostics
Format
  • Enduring Activity
Credits
  • AAPA Category 1 CME credit
  • ACPE contact hours
  • AMA PRA Category 1 Credit™
  • ANCC contact hours
  • Participation
Treatment Considerations in Older Adult Oncology
As the population ages, treatment considerations in older adult patients with cancer become relevant for all specialties. Proper selection of patients is the key to administering effective and safe cancer treatment, including knowing which patients should receive supportive care earlier.
Category
  • Senior Adult Oncology
Format
  • Enduring Activity
Credits
  • AAPA Category 1 CME credit
  • ACPE contact hours
  • AMA PRA Category 1 Credit™
  • ANCC contact hours
  • Participation
Immune Checkpoint Inhibitor Toxicities
Practical knowledge and skills are required to manage the needs of the growing patient population treated with ICIs, particularly as our understanding of best practices for addressing complex toxicities evolves.
Category
  • Management of Immunotherapy-Related Toxicities
Format
  • Enduring Activity
Credits
  • AAPA Category 1 CME credit
  • ACPE contact hours
  • AMA PRA Category 1 Credit™
  • ANCC contact hours
  • Participation
The Role of Biosimilars in Cancer Treatment
Challenges remain in the acceptance of biosimilars by physicians, payers and patients in the U.S., similar to those faced by generic drugs when they were first introduced to the market. Increased education and awareness of the FDA-approval process for biosimilars and increased understanding of the evidence required to demonstrate their safety and efficacy will help to close this practice gap and ensure the acceptance and use of biosimilars in clinical practice.
Category
  • Biosimilars
Format
  • Enduring Activity
Credits
  • AAPA Category 1 CME credit
  • ACPE contact hours
  • AMA PRA Category 1 Credit™
  • ANCC contact hours
  • Participation
The Role of Integrative Medicine in Cancer
Clinician education on the topic of integrative therapies can help patients be informed enough to make the best decisions regarding non-conventional and conventional therapies to optimize their oncologic outcomes and quality of life.
Category
  • Supportive Care Topics
Format
  • Enduring Activity
Credits
  • AAPA Category 1 CME credit
  • ACPE contact hours
  • AMA PRA Category 1 Credit™
  • ANCC contact hours
  • Participation

Pages